Careers  |  Sign In  |  Register

Effect of Pazopanib on Survival After Metastasectomy in Metastatic RCC

Research

Recurrence after metastasectomy is common for patients with metastatic renal cell carcinoma (mRCC). In this study, treating with pazopanib after metastasectomy was shown to offer no additional survival benefit. Leonard Appleman, MD, PhD, who presented the study, stated that while the findings were important, further studies using newer front line treatment options would need to be completed.

Learn more by clicking here.